Date: 19 Aug 2012
Obesity in Polycystic Ovary Syndrome: Insulin Sensitizing Therapy
- Kathleen M. Hoeger
- … show all 1 hide
Polycystic Ovary Syndrome (PCOS) is a common reproductive endocrine disorder in women that is highly associated with obesity. Whether obesity is intrinsic to the disorder or is a result of different lifestyle and environmental concerns is unclear, however obesity influences the risks of PCOS with respect to fertility complications, pregnancy complications and cardiovascular risk. Polycystic ovary syndrome is known to be associated with insulin resistance in both lean and obese individuals. Insulin resistance in fact is felt to be a key feature in the reproductive and metabolic dysfunction of PCOS. There are numerous studies reporting the benefits of insulin sensitizing therapy, specifically metformin and thiazolidinediones, on the features of PCOS and emerging evidence on the impact of these agents on the risk and management of obesity. Weight loss and maintenance of weight reduction has been seen in women and adolescents treated with metformin therapy. Most studies indicate a synergy of metformin with lifestyle therapy in the general population but there are limited data in PCOS.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Stein IF ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181–191.
The ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
Carmina E. Genetic and environmental aspect of polycystic ovary syndrome. J Endocrinol Invest. 2003;26:1151–9.PubMed
Freedman DS. Obesity - United States, 1988–2008. MMWR Surveill Summ. 2011;60(Suppl):73–7.PubMed
Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012; Jul 4. [Epub ahead of print].
Kauffman RP, Baker TE, Baker VM, DiMarino P, Castracane VD. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol. 2008;198:670 e1–7. discussion 670 e7-10.CrossRef
Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1998;38:1165–74.CrossRef
Robinson S, Chan SP, Spacey S, Anyaoku V, Johnston DG, Franks S. Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance. Clin Endocrinol (Oxf). 1992;36:537–43.CrossRef
Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf). 1990;32:213–20.CrossRef
Rich-Edwards JW, Goldman MB, Willett WC, et al. Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol. 1994;171:171–7.PubMed
The ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505–22.CrossRef
Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol. 2011;204:558 e1–6.CrossRef
• Vanky E, Stridsklev S, Skogoy K, et al. PCOS--what matters in early pregnancy?--data from a cross-sectional, multicenter study. Acta Obstet Gynecol Scand. 2011;90:398–404. This study demonstrates a signficant relationship of both hypertension and diabetes risk in PCOS associated with obesity. PubMedCrossRef
Zawadzki JK, Dunaif A. Diagnositic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. Blackwell: Oxford; 1992. p. 377–84.
Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95:2038–49.PubMedCrossRef
Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Obstet Gynecol Surv. 2005;60:589–91.CrossRef
Gambineri A, Patton L, Altieri P, et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes Diabetes. 2012 Jun 14. [Epub ahead of print]).
•• Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35:731–7. This is a long term follow up report to the diabetes prevention program and demonstrates both long term safety and efficacy of metformin as a meaningful strategy in diabetes prevention. The study encompasses 10 years of follow up in total.CrossRef
• Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab. 2012;97:1492–500. This multicenter trial in Finland demonstrates the benefit of pretreatment metformin in obese women with PCOS attempting pregnancy. PubMedCrossRef
•• Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95:E448–55. This is the first multicenter placebo controlled trial of metformin use in pregnancy. There was no demonstrated benefit on pregnancy complications in obese women with PCOS using metformin in pregnancy. PubMedCrossRef
Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 2002;87:1555–9.PubMedCrossRef
Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008;93:4299–306.PubMedCrossRef
• Wiegand S, l’Allemand D, Hubel H, et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol. 2010;163:585–92. This study demonstrated improvement in metabolic parameters with lifestyle intervention in obese adolescents but did not demonstrate additional metformin benefit. However a low dose of metformin was used. PubMedCrossRef
• Lim SS, Norman RJ, Clifton PM, Noakes M. The effect of comprehensive lifestyle intervention or metformin on obesity in young women. Nutr Metab Cardiovasc Dis. 2011;21:261–8. In this trial effective lifestyle intervention was demonstrated in over 200 obese young women. There was no additional benefit seen to metformin use. PubMed
• Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes. 2011;60:477–85. In this randomized trial of metformin or placebo in obese children, metformin reduced body weight and improved body composition. PubMedCrossRef
- Obesity in Polycystic Ovary Syndrome: Insulin Sensitizing Therapy
Current Obesity Reports
Volume 1, Issue 4 , pp 191-198
- Cover Date
- Online ISSN
- Current Science Inc.
- Additional Links
- Polycystic ovary syndrome
- Weight reduction
- Cardiovascular risk
- Adolescent obesity
- Fertility risk
- Pregnancy complications
- Insulin resistance
- Type 2 diabetes
- Insulin sensitizing therapy
- Author Affiliations
- 1. Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, University of Rochester Medical Center, 601 Elmwood Ave. Box 668, Rochester, NY, 14642, USA